Log in
Atrial fibrillation (AF), a form of cardiac rhythm disturbance, significantly increases risk of stroke, heart failure and sudden death. The Division of Imaging Sciences and Biomedical Engineering at King's College London and Philips Healthcare collaborated to develop a platform for guiding cardiovascular catheterisation procedures in patients with AF. The EP Navigator is a commercial, clinical product that integrates pre-acquired magnetic resonance and computer tomography images with real-time X-ray fluoroscopy. This enhances visualisation, thereby reducing procedure time and the patient's exposure to radiation. The EP Navigator is used in around 350 out of 2,000 centres worldwide that carry out ablation therapies for cardiac arrhythmias, despite strong competition.
Key advances in the earlier diagnosis of cancer, leading to better treatment and higher survival rates, have resulted from the commercialisation of unique imaging software that exploits research from the Department of Engineering Science. The software products that came from this research, Volpara™, XD and XRT are now used at major cancer centres worldwide (with approximately 1100 software installations), aiding treatment of tens of thousands of patients every year. Between 2009 and July 2013, Volpara™ scanned over 1.2 million mammograms, enabling the early detection of around 1800 cancers. The products' success has catalysed significant improvements in cancer care, and generated an estimated £9M in sales over the past two years for the spinout companies established to develop them (Matakina, based in New Zealand, and Mirada Medical, based in the UK).
Imaging speed is of critical importance in most Magnetic Resonance (MR) imaging applications. King's College London (KCL) researchers have developed spatiotemporal undersamplings, or "k-t" methods, for three-dimensional (3D) imaging and corresponding image reconstruction methods that have increased the speed of imaging significantly, so that particular scans are now 5-7 fold faster. This has directly impacted the experience of the patient whose overall examination time has been reduced from more than 1 hour to less than 30 minutes depending on the application. The technology has been patented and has been implemented by Philips Healthcare, one of the three major manufacturers of MR equipment. A clinical solution platform for 3D MR cardiac perfusion and quantitative flow imaging, based on the technology developed at KCL, has also been launched by the Swiss company, GyroTools LLC.
UCL's research has led to changes in patient care for men with prostate cancer, through the implementation of less invasive, image-directed treatment and diagnostic strategies, and clinical trials that use these techniques. The use of medical image registration software to deliver high- intensity ultrasound therapy in a targeted manner has been shown to change the treatment plan in half of the patients participating in a clinical study. New biopsy criteria are now used routinely to classify patient risk at University College Hospital, where, since 2009, clinicians have determined the treatment options for more than 741 prostate cancer patients. The scheme has been adopted, by 15 other hospitals in the UK and internationally, where it has become the recommended standard of care, and has been used to treat more than 1,200 patients.
A biomarker is a measurement or physical sign used as a substitute for a clinically meaningful endpoint that measures directly how a patient feels, functions, or survives. Biomarkers can be used to assess changes induced by a therapy or intervention on a clinically meaningful endpoint.
New quantitative image analysis techniques developed at Imperial College have enabled the computation of imaging biomarkers that are now widely used in clinical trials as well as for healthcare diagnostics. This case study illustrates the resulting key impacts including:
The Boujou special effects software was developed from research carried out at the Department of Engineering Science. It enables sophisticated computer generated imagery (CGI) to be quickly and easily added to `real' film footage, facilitating the visual effects that feature so importantly in films such as Harry Potter and X-Men. The software has become an essential tool used by film-makers, TV advert producers, and video game manufacturers, and for instance played a pivotal role in helping `The Curious Case of Benjamin Button' win the 2009 Oscar for Best Visual Effects. Between 2008 and 2013, sales of Boujou totalled £1.37 million and this software boosted productivity and profitability right across the global digital entertainment industry.
Phase unwrapping is an essential algorithmic step in any measurement system or sensor that seeks to determine continuous phase. Instances of such devices are widespread: e.g. image reconstruction in magnetic resonance imaging (MRI), synthetic aperture radar (SAR) by satellite systems, analysis of seismic data in geophysics and optical instrumentation, to name but a few. Without successfully solving the phase unwrapping problem these instruments cannot function.
The topic is well developed and competition among algorithms is fierce. In 2012 alone, some 235 papers, most of which were describing potential new algorithms, were published in the area. But the continuing need for high-speed, automated and robust unwrapping algorithms poses a major limitation on the employability of phase measuring systems.
Working originally within the context of structured light 3D measurement systems, our research has developed new phase image unwrapping algorithms that constitute significance advances in speed, automation and robustness. The work has led to adoption by industry, as well as use in commercial and government research centres around the globe. Our approach since 2010 has been to make these algorithms freely available to end users. Third parties have gone on to translate our algorithms into other languages, widely used numerical software libraries have incorporated the algorithms and there are high profile industrial users.
The Geometric Modelling and Pattern Recognition (GMPR) Group at Sheffield Hallam University (SHU) has developed and patented internationally-known line projection technologies for fast 3D scan, reconstruction and recognition. Three types of impact can be identified: (i) through our patents, we have licensed to companies in Europe and the USA; (ii) these technologies are being transferred to Small and Medium-sized Enterprises (SMEs) across Europe, through the European funded MARWIN and ADMOS projects; and (iii) social and cultural impacts are evidenced by the 3D scanning of representative items from the Museums Sheffield Metalwork Collection which have been made publicly available on the web, and through the `Man of Steel' community project where a landmark sculpture will form a gateway to South Yorkshire and the Sheffield City Region.
Research at the University of Cambridge Department of Engineering (DoEng) has enabled accurate positioning to be added to 2D freehand ultrasound probes to enable the acquisition of large coherent blocks of high-resolution 3D ultrasound image data. The software code base developed in the DoEng was licensed to two separate companies, Schallware and MedaPhor, to enable them each to develop an ultrasound training product. Both companies have sold to more than 30 customers worldwide during the REF impact period; the Cambridge software had a key role in contributing to the innovation and quality of the products developed by both companies, and significantly increased the speed at which they were able to bring these products to market.
SIAscopy is an image analysis method using the physics of image formation. It non-invasively provides near-instant quantitative maps of the key histological components of the skin. The scientific underpinnings were developed by Prof. Claridge's group, patented, and commercialised via a spin-off company Astron Clinica. SIAscopy was incorporated into medical imaging products which improved accuracy of general practitioners in diagnosis of melanoma, a skin cancer, whilst delivering higher cost-effectiveness than best clinical practice. Developed primarily for cancer diagnosis, SIAscopy also found uses in the cosmetics industry. In 2011 the current IPR owner, MedX, estimated the US market opportunity for the technology to be around $1 Billion.